S&P 500 7,500.58 ▲ 80.48 (+1.08%) DOW 51,564.70 ▲ 72.15 (+0.14%) NASDAQ 26,517.93 ▲ 496.28 (+1.91%) US Markets Closed â€ĸ 01:08 AM ET

NWBO

Northwest Biotherapeutics, Inc.

Price Chart
Latest Quote

$0.19

+0.00 (+0.00%)
Current Price
Previous Close $0.19
Open $0.19
Day High $0.20
Day Low $0.19
Volume 514,258
Fetched: 2026-06-21T05:08:38
Stock Information
Shares Outstanding 1.64B
Total Debt $63.99M
Cash Equivalents $1.79M
Revenue $1.50M
Net Income $-45.27M
Sector Healthcare
Industry Biotechnology
Market Cap $312.24M
EPS (TTM) $-0.03
Exchange OQB
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$394.16M
Sales$1.50M
Income$-45.27M
Book/sh$-0.03
Cash/sh$0.00
Employees105
Financial Ratios
Quick Ratio0.02
Current Ratio0.07
Returns & Margins
ROA-62.18%
Operating Margin-2206.48%
Ownership
Insider Ownership4.26%
Institutional Ownership0.06%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-2.71
PEG1.72
P/S208.57
P/B-6.13
Analyst Data
Recommendationnone
Target Price$1.00
Technical Indicators
SMA20$0.20
SMA50$0.21
SMA200$0.24
RSI25.00
ATR0.0136
Shares Float1.61B
Short Float15.09%
Short Ratio13.54
Volatility-0.66
Rel Volume0.54
Performance History
Weeknan%
Monthnan%
Quarternan%
6 Monthsnan%
YTDnan%
Yearnan%
3 Yearsnan%
5 Yearsnan%
10 Yearsnan%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-06-18 $0.19 1,363,900
2026-06-17 $0.19 2,768,000
2026-06-16 $0.19 2,033,900
2026-06-15 $0.19 1,412,400
2026-06-12 $0.20 2,918,600
2026-06-11 $0.19 2,870,300
2026-06-10 $0.19 1,374,300
2026-06-09 $0.19 2,252,100
2026-06-08 $0.20 1,626,400
2026-06-05 $0.20 1,926,700
2026-06-04 $0.21 1,736,400
2026-06-03 $0.20 1,373,200
2026-06-02 $0.21 6,678,700
2026-06-01 $0.22 2,407,000
2026-05-29 $0.23 1,945,600
2026-05-28 $0.22 1,709,600
2026-05-27 $0.21 1,349,900
2026-05-26 $0.21 7,556,600
2026-05-22 $0.23 2,172,300
2026-05-21 $0.23 2,694,400
2026-05-20 $0.25 1,204,600
2026-05-19 $0.25 3,697,100
About Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc., a biotechnology company, engages in the development of personalized immune therapies for cancer. The company develops DCVax, a platform technology which uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It also engages in the development of its lead product candidate DCVax-L in Phase III trials for glioblastoma multiforme brain cancer. In addition, the company develops DCVax-Direct in Phase I trials to treat inoperable solid tumors. Northwest Biotherapeutics, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

Period:
Loading...
Income Statement (Annual)
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Revenue
Total Revenue $1,382,000 $1,932,000 $1,683,000 $1,005,000
Operating Revenue $1,382,000 $1,932,000 $1,683,000 $1,005,000
Expenses
Interest Expense $7,767,000 $5,241,000 $6,068,000 $5,011,000
Total Expenses $67,890,000 $57,440,000 $68,864,000 $53,707,000
Other Income Expense $-9,503,000 $-1,850,000 $-31,783,000 $236,839,000
Other Non Operating Income Expenses $-819,000 $-78,000 $33,000 $-647,000
Net Non Operating Interest Income Expense $-7,767,000 $-5,241,000 $-6,068,000 $-5,011,000
Interest Expense Non Operating $7,767,000 $5,241,000 $6,068,000 $5,011,000
Operating Expense $67,890,000 $57,440,000 $68,864,000 $53,707,000
General And Administrative Expense $33,002,000 $29,710,000 $33,353,000 $33,399,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-83,778,000 $-62,599,000 $-105,032,000 $179,126,000
Net Interest Income $-7,767,000 $-5,241,000 $-6,068,000 $-5,011,000
Normalized Income $-75,094,000 $-60,827,000 $-73,216,000 $5,761,220
Net Income From Continuing And Discontinued Operation $-83,778,000 $-62,599,000 $-105,032,000 $179,126,000
Total Operating Income As Reported $-66,508,000 $-55,508,000 $-67,181,000 $-52,702,000
Net Income Common Stockholders $-85,192,000 $-64,373,000 $-105,032,000 $179,126,000
Net Income $-83,778,000 $-62,599,000 $-105,032,000 $179,126,000
Net Income Including Noncontrolling Interests $-83,778,000 $-62,599,000 $-105,032,000 $179,126,000
Net Income Continuous Operations $-83,778,000 $-62,599,000 $-105,032,000 $179,126,000
Pretax Income $-83,778,000 $-62,599,000 $-105,032,000 $179,126,000
Special Income Charges $-14,393,000 $-5,403,000 $-2,691,000 $-165,000
Operating Income $-66,508,000 $-55,508,000 $-67,181,000 $-52,702,000
Per Share
Diluted EPS $-0.07 $-0.06 $-0.10 $-0.06
Basic EPS $-0.07 $-0.06 $-0.10 $0.21
Other
Tax Effect Of Unusual Items $0 $0 $0 $64,121,220
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-65,283,000 $-53,853,000 $-65,648,000 $-52,763,000
Total Unusual Items $-8,684,000 $-1,772,000 $-31,816,000 $237,486,000
Total Unusual Items Excluding Goodwill $-8,684,000 $-1,772,000 $-31,816,000 $237,486,000
Reconciled Depreciation $2,044,000 $1,733,000 $1,500,000 $586,000
EBITDA (Bullshit earnings) $-73,967,000 $-55,625,000 $-97,464,000 $184,723,000
EBIT $-76,011,000 $-57,358,000 $-98,964,000 $184,137,000
Diluted Average Shares $1,242,237,000 $1,119,191,000 $1,015,852,000 $1,007,869,000
Basic Average Shares $1,242,237,000 $1,119,191,000 $1,015,852,000 $873,517,000
Diluted NI Availto Com Stockholders $-85,192,000 $-64,373,000 $-105,032,000 $179,126,000
Otherunder Preferred Stock Dividend $1,414,000 $1,774,000 $0 $0
Other Special Charges $14,393,000 $5,403,000 $2,691,000 $165,000
Gain On Sale Of Security $5,709,000 $3,631,000 $-29,125,000 $237,651,000
Research And Development $34,888,000 $27,730,000 $35,511,000 $20,308,000
Selling General And Administration $33,002,000 $29,710,000 $33,353,000 $33,399,000
Other Gand A $33,002,000 $29,710,000 $33,353,000 $33,399,000
Fetched: 2026-02-02
Balance Sheet (Annual)
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Assets
Net Tangible Assets $-96,405,000 $-67,691,000 $-130,021,000 $-125,909,000
Total Assets $26,728,000 $27,865,000 $31,323,000 $40,160,000
Total Non Current Assets $22,666,000 $23,740,000 $21,898,000 $22,870,000
Other Non Current Assets $365,000 $361,000 $345,000 $1,036,000
Goodwill And Other Intangible Assets $1,918,000 $1,918,000 $1,918,000 $1,918,000
Other Intangible Assets $1,292,000 $1,292,000 $1,292,000 $1,292,000
Current Assets $4,062,000 $4,125,000 $9,425,000 $17,290,000
Other Current Assets $1,887,000 $1,999,000 $2,460,000 $2,121,000
Cash Cash Equivalents And Short Term Investments $2,175,000 $2,126,000 $6,965,000 $15,169,000
Cash And Cash Equivalents $2,175,000 $2,126,000 $6,965,000 $15,169,000
Prepaid Assets - - - $2,121,000
Debt
Net Debt $60,501,000 $38,666,000 $14,564,000 $17,226,000
Total Debt $67,440,000 $45,560,000 $26,253,000 $37,938,000
Long Term Debt And Capital Lease Obligation $32,734,000 $24,766,000 $10,361,000 $30,382,000
Long Term Debt $28,296,000 $20,312,000 $5,991,000 $25,156,000
Current Debt And Capital Lease Obligation $34,706,000 $20,794,000 $15,892,000 $7,556,000
Current Debt $34,380,000 $20,480,000 $15,538,000 $7,239,000
Other Current Borrowings $34,380,000 $20,480,000 $15,538,000 $7,239,000
Liabilities
Total Liabilities Net Minority Interest $121,215,000 $93,638,000 $159,426,000 $164,151,000
Total Non Current Liabilities Net Minority Interest $52,941,000 $48,434,000 $33,421,000 $30,382,000
Other Non Current Liabilities $4,700,000 $4,950,000 - -
Current Liabilities $68,274,000 $45,204,000 $126,005,000 $133,769,000
Other Current Liabilities $2,426,000 $951,000 $83,803,000 $107,034,000
Payables And Accrued Expenses $31,142,000 $23,459,000 $26,310,000 $19,179,000
Payables $28,382,000 $23,459,000 $26,310,000 $19,179,000
Other Payable $9,721,000 $9,671,000 $8,668,000 $8,232,000
Accounts Payable $18,661,000 $13,788,000 $17,642,000 $10,947,000
Equity
Common Stock Equity $-94,487,000 $-65,773,000 $-128,103,000 $-123,991,000
Total Equity Gross Minority Interest $-94,487,000 $-65,773,000 $-128,103,000 $-123,991,000
Stockholders Equity $-94,487,000 $-65,773,000 $-128,103,000 $-123,991,000
Other Equity Interest $-79,000 $-79,000 $-79,000 $-79,000
Gains Losses Not Affecting Retained Earnings $3,043,000 $1,536,000 $3,145,000 $357,000
Other Equity Adjustments $3,043,000 $1,536,000 $3,145,000 $357,000
Retained Earnings $-1,443,499,000 $-1,359,721,000 $-1,297,122,000 $-1,192,090,000
Preferred Securities Outside Stock Equity $15,507,000 $18,718,000 $23,060,000 $0
Other
Ordinary Shares Number $1,328,600,000 $1,175,459,000 $1,068,400,000 $948,400,000
Share Issued $1,328,600,000 $1,175,459,000 $1,068,400,000 $948,400,000
Tangible Book Value $-96,405,000 $-67,691,000 $-130,021,000 $-125,909,000
Invested Capital $-31,811,000 $-24,981,000 $-106,574,000 $-91,596,000
Working Capital $-64,212,000 $-41,079,000 $-116,580,000 $-116,479,000
Capital Lease Obligations $4,764,000 $4,768,000 $4,724,000 $5,543,000
Total Capitalization $-66,191,000 $-45,461,000 $-122,112,000 $-98,835,000
Additional Paid In Capital $1,344,720,000 $1,291,316,000 $1,164,885,000 $1,066,873,000
Capital Stock $1,328,000 $1,175,000 $1,068,000 $948,000
Common Stock $1,328,000 $1,175,000 $1,068,000 $948,000
Preferred Stock $0 $0 $0 $0
Long Term Capital Lease Obligation $4,438,000 $4,454,000 $4,370,000 $5,226,000
Current Capital Lease Obligation $326,000 $314,000 $354,000 $317,000
Current Accrued Expenses $2,760,000 - - -
Goodwill $626,000 $626,000 $626,000 $626,000
Net PPE $20,383,000 $21,461,000 $19,635,000 $19,916,000
Accumulated Depreciation $-5,553,000 $-3,856,000 $-2,272,000 $-1,084,000
Gross PPE $25,936,000 $25,317,000 $21,907,000 $21,000,000
Leases $17,973,000 $17,785,000 $13,070,000 $13,910,000
Other Properties $4,187,000 $4,183,000 $4,189,000 $4,889,000
Machinery Furniture Equipment $3,691,000 $3,263,000 $2,538,000 $2,109,000
Land And Improvements $85,000 $86,000 $82,000 $92,000
Properties $0 $0 $0 $0
Treasury Shares Number - $0 - -
Construction In Progress - $0 $2,028,000 $0
Fetched: 2026-02-02
Cash Flow Statement (Annual)
Metric 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Free Cash Flow
Free Cash Flow $-58,031,000 $-57,074,000 $-55,677,000 $-44,314,000
Operating Activities
Operating Cash Flow $-57,017,000 $-53,637,000 $-52,775,000 $-38,299,000
Cash Flow From Continuing Operating Activities $-57,017,000 $-53,637,000 $-52,775,000 $-38,299,000
Operating Gains Losses $15,178,000 $2,045,000 $28,512,000 $-239,182,000
Investing Activities
Capital Expenditure $-1,014,000 $-3,437,000 $-2,902,000 $-6,015,000
Investing Cash Flow $-1,014,000 $-3,437,000 $-2,902,000 $-6,015,000
Cash Flow From Continuing Investing Activities $-1,014,000 $-3,437,000 $-2,902,000 $-6,015,000
Financing Activities
Issuance Of Capital Stock $22,418,000 $13,330,000 $28,134,000 $4,070,000
Financing Cash Flow $56,785,000 $52,758,000 $41,968,000 $48,132,000
Cash Flow From Continuing Financing Activities $56,785,000 $52,758,000 $41,968,000 $48,132,000
Net Other Financing Charges $250,000 $4,757,000 $2,566,000 $250,000
Net Preferred Stock Issuance $8,201,000 $13,330,000 $18,669,000 $0
Preferred Stock Issuance $8,201,000 $13,330,000 $18,669,000 $0
Net Common Stock Issuance $14,217,000 $0 $9,465,000 $4,070,000
Common Stock Issuance $14,217,000 $0 $9,465,000 $4,070,000
Other
Repayment Of Debt $-1,433,000 $-385,000 $-5,489,000 $-5,828,000
Issuance Of Debt $34,015,000 $33,339,000 $5,600,000 $29,665,000
Interest Paid Supplemental Data $130,000 $55,000 $912,000 $1,730,000
End Cash Position $2,175,000 $2,126,000 $6,965,000 $15,169,000
Beginning Cash Position $2,126,000 $6,965,000 $15,169,000 $9,983,000
Effect Of Exchange Rate Changes $1,295,000 $-523,000 $5,505,000 $1,368,000
Changes In Cash $-1,246,000 $-4,316,000 $-13,709,000 $3,818,000
Proceeds From Stock Option Exercised $1,535,000 $1,717,000 $11,157,000 $19,975,000
Net Issuance Payments Of Debt $32,582,000 $32,954,000 $111,000 $23,837,000
Net Long Term Debt Issuance $32,582,000 $32,954,000 $111,000 $23,837,000
Long Term Debt Payments $-1,433,000 $-385,000 $-5,489,000 $-5,828,000
Long Term Debt Issuance $34,015,000 $33,339,000 $5,600,000 $29,665,000
Net PPE Purchase And Sale $-1,014,000 $-3,437,000 $-2,902,000 $-6,015,000
Purchase Of PPE $-1,014,000 $-3,437,000 $-2,902,000 $-6,015,000
Change In Working Capital $10,003,000 $-3,695,000 $7,209,000 $2,725,000
Change In Other Current Liabilities $64,000 $242,000 $135,000 $26,000
Change In Other Current Assets $-7,000 $-12,000 $625,000 $-179,000
Change In Payables And Accrued Expense $9,845,000 $-4,426,000 $6,846,000 $-597,000
Change In Payable $9,845,000 $-4,426,000 $6,846,000 $-597,000
Change In Account Payable $9,845,000 $-4,426,000 $6,846,000 $-597,000
Change In Prepaid Assets $101,000 $501,000 $-397,000 $3,475,000
Other Non Cash Items $3,795,000 $2,450,000 $2,738,000 $2,948,000
Stock Based Compensation $3,456,000 $4,408,000 $12,298,000 $15,498,000
Unrealized Gain Loss On Investment Securities $-7,715,000 $2,021,000 $0 $0
Depreciation Amortization Depletion $2,044,000 $1,733,000 $1,500,000 $586,000
Depreciation And Amortization $2,044,000 $1,733,000 $1,500,000 $586,000
Depreciation $2,044,000 $1,733,000 $1,500,000 $586,000
Gain Loss On Investment Securities $785,000 $-3,358,000 $25,821,000 $-239,347,000
Net Income From Continuing Operations $-83,778,000 $-62,599,000 $-105,032,000 $179,126,000
Net Business Purchase And Sale - - $0 $0
Purchase Of Business - - $0 $0
Net Short Term Debt Issuance - - - $0
Short Term Debt Payments - - - $0
Short Term Debt Issuance - - - $0
Fetched: 2026-02-02